Drug Profile
Research programme: cancer therapeutics - Emerald Biostructures/Selexagen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Emerald BioStructures; Selexagen Therapeutics
- Developer Emerald BioStructures
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 26 Jan 2011 Early research in Cancer in USA (unspecified route)